Community Lipid Management Service

Tender description

NHS BLMK Clinical Commissioning Group has awarded a contract to Evexia Health Ltd following an 'Open' procurement process to deliver a new Community Lipid Management Service. The purpose of the Community Lipid Service is to provide a consistent, evidence-based approach to lipid management across BLMK CCG. The Community Lipid Clinic will form part of a new pathway developed with key stakeholders across BLMK, in line with evidenced-based best practice. The service will be funded to provide clinical activity to optimise lipid management in populations at very high risk of CVD (as defined by the commissioner) and provide clinical assessment for familial hypercholesterolemia in people meeting appropriate clinical criteria (as defined by the commissioner), in line with locally developed evidence-based pathways. The Community Lipid Clinic will accept referrals of people meeting the relevant clinical criteria who are registered with a GP practice in Bedfordshire, Luton and Milton Keynes Integrated Care System. Lot 1: NHS BLMK CCG secured Pathway Transformation Funding (PTF) to support the adoption of a new lipid management pathway and the establishment of community lipid services. The Community Lipid service will offer: • A full assessment of people referred with CVD and/or FH and also uncontrolled hypercholesterolaemia or mixed dyslipidemia, including review of current and previous lipid lowering treatments, adherence with treatment regimes and any reasons for discontinuation. • Pharmacological management and monitoring of effectiveness and tolerability in line with pathways agreed with the commissioner. • Requesting of appropriate pathology tests at appropriate intervals through the relevant pathology system. • Electronic prescription of relevant medications, in sufficient quantity to meet the requirements for uptitration between review contacts. • Comprehensive documentation of each clinical contact in the shared clinical record on SystmOne. • Support for self-management and education on the significance of managing cardiovascular risk factors, including cholesterol. • Appropriate signposting to other services to support optimisation of health and wellbeing, including weight management, smoking cessation, alcohol support and talking therapies. • Onward referral to specialist lipid services of patients with uncontrolled lipids despite maximum tolerated oral therapy, in line with criteria and pathways agreed with the commissioner. • Clinical assessment of people with clinical features suggestive of suspected FH (as defined by the commissioner), with onward referral as appropriate to specialist lipid services. • Clear treatment plans with appropriate patient-driven uptitration of therapy, timing of repeat lipid testing and scheduling of follow-up to allow maximal impact from each clinical contact.